The history of Soviet recombinant interferon is often presented as a story of scientific achievement: Soviet molecular biologists successfully constructed a synthetic gene for human interferon alpha-2, developed methods for expressing it in “Escherichia coli,” and eventually produced the recombinant pharmaceutical Reaferon on an industrial scale. Such a narrative is not incorrect, but it risks reducing a remarkably complex technological history to a sequence of laboratory breakthroughs.

The development of recombinant interferon in the Soviet Union was not simply a matter of discovering how to construct a gene. It required the simultaneous mobilisation of scientists, research institutes, industrial organisations, pharmaceutical manufacturers, state agencies, fermentation equipment, biological materials, clinical facilities, and administrative structures. The technology could only become a practical pharmaceutical once these diverse components had been brought into a sufficiently coherent system.

Thomas P. Hughes’s concept of the “Large Technological System (LTS)” provides a useful framework for understanding this process. For Hughes, technological systems are composed not merely of machines and scientific discoveries but of heterogeneous components—including physical artefacts, organisations, scientific knowledge, legislative and administrative structures, and human actors—that must be coordinated in order for a technological system to function. System builders play a particularly important role because they identify problems, connect otherwise separate components, and construct relationships between them.

Technological systems also develop unevenly. A particular component may become a “reverse salient,” lagging behind the development of the rest of the system and thereby obstructing further expansion. System growth consequently involves not only invention but also the continuous resolution of such critical problems.

Viewed through this framework, the Soviet recombinant interferon programme was a process of system building. Its history reveals the considerable capacity of the late Soviet scientific and industrial establishment to mobilise resources across institutional boundaries, while simultaneously exposing the difficulties involved in transforming experimental biotechnology into reliable industrial production.

The importance of Academician Yurii Anatol’evich Ovchinnikov therefore lies not simply in his role as an influential scientist but in his function as a system builder who helped connect fundamental molecular biology with industrial biotechnology, pharmaceutical production, and state administration. The eventual emergence of Reaferon was consequently the result not of a single scientific breakthrough but of the gradual construction and stabilisation of a large technological system.

The Soviet recombinant interferon programme was launched in 1979 under the leadership of Yurii Anatol’evich Ovchinnikov, the influential Soviet bioorganic chemist and Academician. From its beginning, the programme possessed characteristics that distinguish it from a conventional laboratory research project. It brought together organisations belonging to different institutional and technological environments, most notably the USSR Academy of Sciences and the industrial biotechnology complex represented by Biopreparat.

One of the principal centres was Ovchinnikov’s Moscow-based M.M. Shemyakin Institute of Bioorganic Chemistry. Another was the All-Union Scientific-Research Institute of Molecular Biology (VNIIMB) at Kol’tsovo, which belonged to the expanding Soviet biotechnology infrastructure. These institutions possessed different forms of expertise. The Shemyakin Institute was particularly important for chemical synthesis and molecular construction, while VNIIMB possessed expertise in molecular biology and the biological expression of recombinant products.

This division of labour is significant when considered through Hughes’s concept of a technological system. The problem facing Soviet scientists was not simply how to synthesise a gene. A synthetic gene that remained confined to a laboratory was of limited practical value. It had to become connected to a biological host, production technology, purification procedures, pharmaceutical testing, industrial fermentation, and ultimately a manufacturing and distribution infrastructure. Each of these elements constituted a component of the emerging system.

Ovchinnikov’s political and scientific influence was particularly important because the Soviet scientific system contained significant institutional divisions between fundamental research and practical application. The Academy of Sciences, industrial ministries, medical institutions, and production organisations operated according to different administrative priorities. A discovery made within an academic institute did not automatically become an industrial technology. The transition from knowledge to production required organisational mediation.

In Hughes’s terminology, this makes Ovchinnikov more than a scientific leader. He can be understood as a “system builder.” His importance lay partly in his capacity to identify a technologically significant objective and mobilise the institutional components required to pursue it. His influence allowed the programme to bring together organisations that otherwise might have remained separated by administrative boundaries.

The programme consequently developed around two principal scientific groups. At the Shemyakin Institute, Academician Mikhail Nikolaevich Kolosov directed work concerned with the chemical synthesis and construction of the interferon gene. At VNIIMB, Professor Lev Stepanovich Sandakhchiev led research concerned with biological and molecular-biological aspects of the recombinant system. The division was not merely administrative. It represented an early form of “system integration,” in which different areas of specialised expertise were connected around a common technological objective.

By 1983, this network had produced a major scientific result. Kolosov and his colleagues reported in “Vestnik Akademii Nauk SSSR” the successful creation of an artificial gene coding for alpha-2 interferon that was functional in “Escherichia coli.” The achievement demonstrated that Soviet researchers possessed the scientific capabilities necessary to participate in the rapidly developing field of genetic engineering.

Yet from the perspective of technological-system history, the achievement was simultaneously a beginning and an incomplete accomplishment. The synthetic gene solved one of the programme’s critical problems, but it did not solve the problem of producing a pharmaceutical. The emerging system still required additional components.

Raymond Zilinskas’s contemporary account provides further details of the construction strategy. The synthetic gene lacked its first codon, allowing it to be joined to “E. coli” DNA during the cloning process. The researchers used a tryptophan promoter, an approach that had already been employed elsewhere and which facilitated comparison with international research. Such details illustrate the international character of Soviet biotechnology. Although the programme was embedded within a Soviet institutional system, its researchers operated within an international technological environment in which experimental techniques, scientific publications, and competing achievements shaped the definition of technological progress.

The Soviet achievement therefore cannot be understood simply as an isolated demonstration of national scientific capability. It represented the successful connection of chemical synthesis, molecular biology, genetic engineering, and biological expression. In Hughes’s terms, several previously distinct components had begun to form a coherent technological system.

The construction of the interferon gene, however, did not automatically produce an industrial technology. The next problem was “scale.”

This distinction between scientific demonstration and industrial production is central to the history of the Soviet programme. A recombinant organism could produce interferon under controlled experimental conditions without necessarily providing an economically or technologically viable manufacturing process. Production yields had to be increased, genetic stability had to be maintained, degradation had to be controlled, and the biological product had to be recovered and purified at sufficient scale.

The involvement of the All-Union Scientific-Research Institute of Genetics and Selection of Industrial Microorganisms (VNIIGenetika) illustrates this transition. According to Zilinskas, researchers at the institute worked on improving production yields, increasing the stability of the RNA matrix, and developing an improved genetic sequence intended to prevent degradation of interferon by cellular proteases.

These problems can be understood through Hughes’s concept of the “reverse salient.” The synthetic gene itself had become a successful component of the technological system. Yet the production process remained comparatively underdeveloped. As the system advanced, weaknesses that had previously been less important became increasingly visible.

The reverse salient therefore shifted.

At one stage, the central problem was:

Could Soviet scientists construct a functional synthetic interferon gene?

After the 1983 breakthrough, the question became:

Could that gene produce sufficient quantities of stable interferon?

Later, the questions became:

Could the product be purified?

Could it be manufactured consistently?

Could it satisfy medical standards?

Could it be tested clinically?

Could it be packaged and distributed?

The history of Reaferon is consequently a history of “successive reverse salients.” Solving one technological problem did not complete the system; instead, it exposed the next problem that had to be solved.

This helps explain why the programme required so many institutions. What might appear in retrospect as a single project was actually a chain of interdependent technological activities. Molecular biology could not by itself solve problems belonging to industrial microbiology. Industrial microbiology could not resolve questions of pharmaceutical purification. Pharmaceutical production could not substitute for clinical trials. The system expanded because each solution generated new requirements.

The significance of this transition is particularly visible in Academician Evgenii Davidovich Sverdlov’s presentation to the Interdepartmental Scientific Council on Medicine on 9 January 1984. Reported by “Izvestiya” the following day, Sverdlov emphasised the extraordinary potential of recombinant technology for increasing the supply of interferon.

He compared the production of interferon from donated blood with recombinant production. According to the figures reported by Sverdlov, one litre of donor blood yielded approximately one dose of interferon, whereas the equivalent volume of bacterial suspension could yield one thousand times more. He further stated that a fermenter at the Ladyzhyn plant of Glavmikrobioprom had produced five million doses in one and a half work shifts. Producing the same quantity from donor blood, he claimed, would have required twenty-five million donors.

The numbers illustrate the enormous technological promise of recombinant production. The significance of the technology was not simply that it represented a more sophisticated method of making interferon. It potentially transformed the material basis of production. Interferon no longer had to depend upon the biological resources of human donors. A microbial production system could, in principle, transform genetic information into an industrially reproducible pharmaceutical product.

Nevertheless, the historical record also reveals the difference between “technological possibility and technological stabilisation.” In March 1987, “Pravda” reported that the Ladyzhyn Enzyme Preparations Plant had manufactured only 50,000 doses of interferon during the entirety of 1986. The contrast with Sverdlov’s reported five million doses in one and a half shifts is striking.

Rather than simply treating these figures as contradictory, the discrepancy can be interpreted through Hughes’s framework. The five-million-dose figure may have represented an experimental or semi-industrial achievement under particular conditions rather than a sustainable routine production rate. The later figure suggests that the broader technological system had not necessarily acquired the capacity to reproduce that result consistently.

In other words, the fermenter could function as an isolated technological artefact without the entire production system necessarily being capable of supporting its continuous operation at the same level.

This distinction is crucial. A technological system is more than the sum of its successful experiments. It requires the integration of components over time. Raw materials, equipment, trained personnel, maintenance, purification, quality control, pharmaceutical standards, administrative coordination, and distribution all have to function together. A spectacular production run demonstrates possibility; a functioning industry demonstrates “system stability.”

Sverdlov himself acknowledged that the work was not yet complete. He described the programme as involving scientists and specialists from the D. I. Ivanovsky Institute of Virology, the N. F. Gamaleya Institute of Epidemiology and Microbiology, the Institute of Genetics and Selection of Industrial Microorganisms, the Institute of Technology of Blood Substitutes and Hormonal Preparations, and the Institute of Organic Synthesis of the Academy of Sciences of the Latvian SSR.

This list is almost a map of the emerging technological system.

Each institution addressed a different component of the problem. The programme had to connect molecular biology with industrial microbiology, medicine, pharmaceutical technology, experimental testing, and chemical synthesis. Its complexity increased precisely because its ambitions expanded.

Sverdlov’s discussion of preclinical and clinical trials, purification, and packaging demonstrates that the production of recombinant interferon was approaching a new set of reverse salients. The problem was no longer simply whether the technology worked. It was whether the resulting product could become a standardised pharmaceutical.

The recombinant alpha-2 interferon preparation eventually received the name “Reaferon.” Before clinical evaluation, the preparation underwent preclinical trials at the Biopreparat Institute of Immunology in Lyubuchany, involving several other Soviet research organisations. These included the N. F. Gamaleya Scientific-Research Institute of Epidemiology and Microbiology in Moscow, the Scientific-Research Institute of Biological Testing of Chemical Compounds at Staraya Kupavna, and the Scientific-Research Institute of Experimental Medicine in Sukhumi.

The growing number of participating organisations demonstrates the expansion of the technological system. The original scientific problem—constructing a recombinant interferon gene—had evolved into a much broader pharmaceutical problem. Reaferon had to become not merely biologically functional but medically usable.

This required new system components.

Immunology was required to understand biological effects. Experimental medicine was necessary for preclinical evaluation. Pharmaceutical institutions were responsible for formulation and standards. Clinical institutions would eventually assess the preparation in humans. Production facilities had to manufacture it at scale.

Thus, the development of Reaferon illustrates what Hughes calls “system growth.” Technological systems grow not simply by adding more machines but by incorporating new forms of knowledge, organisation, infrastructure, and institutional authority. As the Soviet interferon programme expanded, the definition of what counted as relevant expertise expanded with it.

This also helps explain why the history cannot be reduced to the achievements of the Shemyakin Institute. The institute was indispensable to the original molecular breakthrough, but no single institution possessed the complete technological system required to turn that breakthrough into a pharmaceutical.

The programme’s institutional complexity was therefore not evidence of inefficiency alone. It was also a consequence of technological maturity. As the technology became more ambitious, its system boundaries expanded.

The most important indication that the Soviet recombinant interferon system was approaching industrial maturity came in 1990, when the first large-scale series production of recombinant alpha-2 interferon took place at Biopreparat’s All-Union Scientific-Research Institute of Applied Enzymology in Vilnius, Lithuania.

Production was carried out using a 1,000-litre fermenter at the institute’s pilot plant, producing approximately one million doses of interferon. The resulting preparation was transferred to Kaunas for packaging at the Factory of Endocrine Preparations and the Sanitas Experimental Production Factory.

The significance of this development lies precisely in the integration of multiple technological components.

The fermenter provided the physical infrastructure for biological production. The institute supplied technical and organisational expertise. The pharmaceutical facilities in Kaunas provided packaging capabilities. Together, these components transformed recombinant interferon from a laboratory product into something approaching an industrial commodity.

This was therefore more than an increase in production volume. It represented a significant degree of “system integration.”

The management of the Institute of Applied Enzymology reportedly believed that the technology would soon be capable of supplying the requirements of the entire Soviet market. Such confidence suggests that the system had reached a point at which its participants could imagine further expansion.

Yet the historical timing of this achievement is profoundly important.

The first major series production occurred in 1990—just as the Soviet technological and political system that had constructed it was approaching collapse.

The recombinant interferon programme therefore reached a crucial stage of technological maturity at precisely the moment when its broader institutional environment was becoming unstable.

Hughes’s concept of “technological momentum” is particularly useful for understanding this final stage. Technological momentum describes the way technological systems, once established, acquire increasing influence over the societies and institutions in which they operate. A mature technological system is not easily dismantled because it incorporates physical infrastructure, specialised knowledge, organisational relationships, professional expertise, and expectations about future development.

The Soviet recombinant interferon system had accumulated many of these characteristics by 1990. It possessed research institutions, industrial facilities, specialised personnel, fermentation infrastructure, pharmaceutical organisations, and interinstitutional relationships. Its existence had created expectations about future production and technological development.

But technological momentum did not make the system immune to political transformation.

The dissolution of the USSR in 1991 radically altered the institutional environment in which Soviet biotechnology operated. Research organisations that had previously been integrated into a unified state system were now distributed among independent states. Facilities in Russia, Ukraine, Lithuania, and other former Soviet republics entered different political and economic systems. Funding structures changed, industrial supply chains were disrupted, and institutions that had once been components of a single technological system no longer necessarily belonged to the same political order.

This is one of the most revealing aspects of the Reaferon story. The collapse of the Soviet Union did not erase the technological system overnight. Its physical infrastructure, scientific knowledge, trained personnel, and institutional memory persisted. The system therefore survived in fragmented forms even as the political structure that had originally coordinated it disappeared.

The history of recombinant interferon consequently demonstrates both the strength and the fragility of Soviet technological organisation. The Soviet state had demonstrated an extraordinary capacity to construct a complex biotechnology system by connecting research institutes, industrial organisations, medical institutions, and state agencies. Yet the system’s dependence upon centralised institutional coordination also left it vulnerable to political disintegration.

Before recombinant technology, Soviet interferon production depended principally upon donated human blood in the form of leukocyte interferon. This imposed fundamental limitations. Production depended upon the availability of donors, while purification, standardisation, safety, and large-scale manufacturing presented considerable difficulties.

Recombinant technology potentially transformed this situation by changing the relationship between biological information and pharmaceutical production. Instead of obtaining interferon directly from human biological material, scientists could reproduce the relevant genetic information and employ microorganisms as production systems.

This transformation illustrates the deeper historical significance of the Soviet recombinant interferon programme. Its importance was not exhausted by the creation of Reaferon. The programme contributed to the construction of a technological infrastructure and knowledge base that could support subsequent recombinant pharmaceutical production in Russia and other post-Soviet contexts.

From a Hughesian perspective, the most important legacy was therefore not simply the pharmaceutical itself but the “technological system built around it.”

The programme produced scientific knowledge, but it also produced institutions capable of applying that knowledge. It developed specialised personnel, production technologies, fermentation capacity, pharmaceutical procedures, and organisational relationships. These components could potentially survive the disappearance of the political system that had originally assembled them.

At the same time, the history warns against interpreting Soviet biotechnology as an uncomplicated success story. The programme repeatedly encountered reverse salients. The construction of a functional gene did not guarantee high production yields. High production yields did not guarantee stable industrial production. Industrial production did not automatically guarantee pharmaceutical standardisation. Experimental success did not necessarily translate into routine manufacturing.

The striking discrepancy between Sverdlov’s 1984 production claim and the much lower Ladyzhyn output reported several years later illustrates precisely this problem. Soviet scientists could demonstrate technological capabilities that the larger system struggled to reproduce consistently. The distinction between “demonstration and stabilization” therefore lies at the heart of the history.

The Soviet recombinant interferon programme is best understood not simply as a scientific breakthrough but as an attempt to construct a large technological system around a new form of biotechnology. Beginning in 1979, the programme progressively connected molecular biology, chemical synthesis, genetic engineering, industrial microbiology, fermentation technology, pharmaceutical production, medical research, clinical testing, and state administration. The successful construction of a synthetic interferon gene in the early 1980s represented an important breakthrough, but it was only one component of a much larger process.

Thomas Hughes’s concept of the Large Technological System makes it possible to understand why the subsequent history was so institutionally complex. The programme required “system builders” such as Ovchinnikov, who could connect otherwise separated institutions and mobilise political and scientific resources. It required the creation of relationships between heterogeneous system components, from research institutes and industrial organisations to fermenters and pharmaceutical facilities. And as the programme expanded, it repeatedly encountered “reverse salients” that had to be overcome before the technology could advance to the next stage.

The history of Reaferon therefore reveals an important paradox in late Soviet science. The Soviet system possessed considerable capacity for technological mobilisation. Under favourable political circumstances, it could coordinate institutions that normally operated separately and direct them toward a common strategic objective. Yet the very complexity of biotechnology meant that scientific breakthroughs could not automatically be converted into stable industrial production. The five-million-dose production figure reported by Sverdlov and the much smaller subsequent output at Ladyzhyn demonstrate the difference between proving that a technology could work and constructing a system capable of making it work reliably.

By 1990, the production of approximately one million doses at the Institute of Applied Enzymology in Vilnius suggested that the recombinant interferon system had achieved a significant degree of technological integration. Yet this achievement occurred at the threshold of the Soviet Union’s dissolution. The resulting political transformation fragmented the institutional structure through which the system had been constructed, even though its knowledge, infrastructure, personnel, and technological practices survived.

The history of Soviet recombinant interferon is therefore ultimately a history of “system building under conditions of political centralisation and technological complexity.” Reaferon was not created by a laboratory alone. It emerged from a network of institutions and technologies that had gradually been assembled around the problem of converting genetic information into an industrial pharmaceutical. Its historical significance lies precisely in this process. The recombinant interferon programme demonstrated that Soviet science could construct a sophisticated biotechnology system capable of connecting fundamental research to industrial production, while also revealing the organisational and technological difficulties involved in maintaining such a system.

In this sense, the most important achievement of the programme may not have been the synthetic interferon gene itself. It was the creation of the technological infrastructure necessary to make that gene matter.

References

  • Pravda. (1987, March). [Report on interferon production at the Ladyzhyn Enzyme Preparations Plant].
  • Reaferon: Conference proceedings, Kol’tsovo, 25–29 January 1993. (1993).
  • Amann, R., & Cooper, J. M. (Eds.). (1982). Industrial innovation in the Soviet Union. Yale University Press.
  • Amann, R., Cooper, J. M., & Davies, R. W. (Eds.). (1977). The technological level of Soviet industry. Yale University Press.
  • Goeddel, D. V., Yelverton, E., Ullrich, A., et al. (1980). Human leukocyte interferon produced by E. coli is biologically active. Nature, 287, 411–416.
  • Graham, L. R. (1993). Science in Russia and the Soviet Union: A short history. Cambridge University Press.
  • Hughes, T. P. (1976). The development phase of technological change. Technology and Culture, 17(3), 423–431.
  • Hughes, T. P. (1983). Networks of power: Electrification in Western society, 1880–1930. Johns Hopkins University Press.
  • Hughes, T. P. (1986). The seamless web: Technology, science, etcetera, etcetera. Social Studies of Science, 16(2), 281–292.
  • Hughes, T. P. (1987). The evolution of large technological systems. In W. E. Bijker, T. P. Hughes, & T. J. Pinch (Eds.), The social construction of technological systems: New directions in the sociology and history of technology (pp. 51–82). MIT Press.
  • Josephson, P. R. (1996). New Atlantis revisited: Akademgorodok, the Siberian city of science. Princeton University Press.
  • Kolosov, M. N., et al. (1983). [Report on the construction of an artificial alpha-2 interferon gene]. Vestnik Akademii Nauk SSSR, (7), 35–41.
  • Nagata, S., Taira, H., Hall, A., Johnsrud, L., Streuli, M., Ecsödi, J., Boll, W., Cantell, K., & Weissmann, C. (1980). Synthesis in E. coli of a polypeptide with human leukocyte interferon activity. Nature, 284, 316–320.
  • Ovchinnikov, Y. A. (1982). Biotechnology and its place in scientific and technological progress. Vestnik Akademii Nauk SSSR, 4, 4–17.
  • Pestka, S. (1983). The interferons: An overview. Methods in Enzymology, 78, 3–14.
  • Rimmington, A. (1988). Biotechnology in the USSR [Doctoral dissertation, University of Birmingham].
  • Rimmington, A. (1992). Technology and transition: A survey of biotechnology in Russia, Ukraine and the Baltic States. Quorum Books.
  • Sverdlov, E. D. (1984, January 10). [Report on recombinant interferon production]. Izvestiya, (10).
  • Zilinskas, R. (1984). Biotechnology in the U.S.S.R., Part 1. Bio/Technology, 2, 610–615.
  • Zilinskas, R. (1984). Biotechnology in the U.S.S.R., Part 2. Bio/Technology, 2, 686–692.